The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The general function of the committees is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Document
Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safet...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 46081
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” thefederalregister.org (October 3, 2017), https://thefederalregister.org/documents/2017-21170/joint-meeting-of-the-psychopharmacologic-drugs-advisory-committee-and-the-drug-safety-and-risk-management-advisory-commi.